Madrigal Pharmaceuticals, Inc. (MDGL) Revenue by Segment & Business Profile
Rezdiffra (thyroid hormone receptor beta agonist) for MASH was 100.0% of Madrigal Pharmaceuticals, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MDGLMadrigal Pharmaceuticals, Inc.Follow MDGL — free
—
Price chart with a free account
- Market cap
- 10.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
What the company does
Madrigal Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $1.3 billion as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Madrigal Pharmaceuticals, Inc. — questions
- What does Madrigal Pharmaceuticals, Inc. do?
- Madrigal Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $1.3 billion as of 2026-06-30.
- How does Madrigal Pharmaceuticals, Inc. make money?
- By the lines it reports in its SEC filings: Rezdiffra (thyroid hormone receptor beta agonist) for MASH 100.0% of revenue.
Every figure on this page comes from Madrigal Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.